Abstract:
There is disclosed pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner as a target for intervention. There is further disclosed a method of using cyclophilins, anti-cyclophilin antibodies, and pegylated cyclosporin A as a treatment for HIV-infection. The present invention further provides screening assays for the identification of compounds which inhibit the interaction of cyclophilin and its cellular receptor.